Literature DB >> 9365886

High prevalence of GBV-C hepatitis G virus infection in a rural South African population.

T J Tucker1, S J Louw, S C Robson, S Isaacs, R E Kirsch.   

Abstract

A novel virus, GBV-C/hepatitis G virus (GBV-C/HGV), has been cloned and characterised recently. GBV-C/HGV global epidemiology and risk factors for acquisition are currently unclear. We aimed to establish the determinants of this infection in a rural South African (SA) population. The study population included two samples, namely a community-based sample, and consenting persons from a nonspecialist outpatient department in the same district. A questionnaire regarding demographic details and putative risk factors was administered; blood samples were taken on which a polymerase chain reaction (PCR) was performed for both 5'NCR and NS5a regions of GBV-C/HGV using commercially available primers and probes. Two hundred and forty-nine people were studied with a mean GBV-C/HGV prevalence of 10.4%. Outpatient department and community prevalences differed significantly (18.0% and 6.3%, respectively, P = 0.004). GBV-C/HGV infection was associated with excessive alcohol consumption (P = 0.02; OR, 4.18) and a lack of waterborne sewerage (P = 0.04). PCR amplification of the NS5a region of all but two South African GBV-C/HGV positive samples showed poor reactivity. The prevalence of GBV-C/HGV in rural SA appears to be higher than that reported from Europe and North America. Infection appeared to be associated with excess alcohol intake and a history of previous blood transfusion. The discrepant NS5a and 5'NCR PCR sensitivity in this study raises the possibility of genetic differences in southern African GBV-C/HGV.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Alcohol Drinking; Behavior; Blood Transfusion; Demographic Factors; Developing Countries; Diseases; English Speaking Africa; Examinations And Diagnoses; Hepatitis; Laboratory Examinations And Diagnoses; Measurement; Population; Population Characteristics; Prevalence; Research Methodology; Research Report; Rural Population; Sampling Studies; South Africa; Southern Africa; Studies; Surveys; Treatment; Viral Diseases

Mesh:

Year:  1997        PMID: 9365886

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  GB virus C/hepatitis G virus (GBV-C/HGV): still looking for a disease.

Authors:  M Sathar; P Soni; D York
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

Review 2.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

3.  Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections.

Authors:  C Menéndez; J M Sánchez-Tapias; P L Alonso; M Giménez-Barcons; E Kahigwa; J J Aponte; H Mshinda; M M Navia; M T Jiménez de Anta; J Rodés; J C Saiz
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  Age related prevalence of hepatitis G virus in South Africans.

Authors:  M J Mphahlele; S Aspinall; R Spooner; W F Carman
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

5.  PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort.

Authors:  Colin P Sharp; William F Gregory; Louise Hattingh; Amna Malik; Emily Adland; Samantha Daniels; Anriette van Zyl; Jonathan M Carlson; Susan Wareing; Anthony Ogwu; Roger Shapiro; Lynn Riddell; Fabian Chen; Thumbi Ndung'u; Philip J R Goulder; Paul Klenerman; Peter Simmonds; Pieter Jooste; Philippa C Matthews
Journal:  Wellcome Open Res       Date:  2017-04-07

Review 6.  Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.

Authors:  Mehdi Samadi; Vahid Salimi; Mohammad Reza Haghshenas; Seyed Mohammad Miri; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Virol J       Date:  2022-03-09       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.